Alkermes Inc. plc
ALKS
ALKS: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
moreShow ALKS Financials
Recent trades of ALKS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ALKS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Jan. 03, 2023
-
Patent Title: Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties Dec. 27, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Mar. 29, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Substituted pyridines as inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Hetero-halo inhibitors of histone deacetylase Feb. 16, 2021
-
Patent Title: Single chain fc fusion proteins Jan. 05, 2021
-
Patent Title: Compositions for modulating il-10 immunostimulatory and anti-inflammatory properties Jul. 02, 2019
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Jan. 22, 2019
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Jul. 17, 2018
-
Patent Title: Peripherally acting opioid compounds Oct. 03, 2017
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Aug. 30, 2016
-
Patent Title: Peripherally acting opioid compounds Aug. 16, 2016
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Jun. 07, 2016
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Mar. 29, 2016
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Oct. 13, 2015
-
Patent Title: Selective opioid compounds May. 26, 2015
-
Patent Title: Process for the synthesis of quaternary amine compounds May. 12, 2015
-
Patent Title: Polymorphic forms of naltrexone Mar. 10, 2015
-
Patent Title: Peripherally acting opioid compounds Feb. 24, 2015
-
Patent Title: Polymorphic forms of naltrexone May. 27, 2014
-
Patent Title: Polymorphic forms of naltrexone Mar. 05, 2013
-
Patent Title: Selective opioid compounds Jan. 15, 2013
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Naltrexone long acting formulations and methods of use Apr. 05, 2011
-
Patent Title: Pulmonary delivery for levodopa Feb. 01, 2011
-
Patent Title: Residual solvent extraction method and microparticles produced thereby Jan. 25, 2011
-
Patent Title: Formulations for spray-drying large porous particles Oct. 05, 2010
-
Patent Title: Inhalable sustained therapeutic formulations Jul. 13, 2010
-
Patent Title: Particles for inhalation having sustained release properties Mar. 16, 2010
Federal grants, loans, and purchases
Followers on ALKS's company Twitter account
Number of mentions of ALKS in WallStreetBets Daily Discussion
Recent insights relating to ALKS
Recent picks made for ALKS stock on CNBC
ETFs with the largest estimated holdings in ALKS
Flights by private jets registered to ALKS